Refining oxytocin therapy for autism: context is key
- PMID: 34880473
- PMCID: PMC8816821
- DOI: 10.1038/s41582-021-00602-9
Refining oxytocin therapy for autism: context is key
Abstract
A recent clinical trial found no effect of chronic intranasal oxytocin on social behaviour in children with autism spectrum disorders. The result is not surprising, as oxytocin facilitates social learning but does not directly cause prosocial behaviour. In future trials, oxytocin should be paired with behavioural therapy to enhance learning and improve social behaviour.
Conflict of interest statement
Competing interests
The authors declare no competing interests.
Figures

Comment on
-
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.N Engl J Med. 2021 Oct 14;385(16):1462-1473. doi: 10.1056/NEJMoa2103583. N Engl J Med. 2021. PMID: 34644471 Free PMC article. Clinical Trial.